La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !
Cassava Sciences Gestione
Gestione criteri di controllo 3/4
Cassava Sciences' Il CEO è Rick Barry, nominato in Sep2024, ha un mandato di 3.25 anni. possiede direttamente 0.98% delle azioni della società, per un valore di $ 12.68M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 1.9 anni e 9.9 anni.
Informazioni chiave
Rick Barry
Amministratore delegato
US$546.2k
Compenso totale
| Percentuale dello stipendio del CEO | n/a |
| Mandato del CEO | no data |
| Proprietà del CEO | 1.0% |
| Durata media del management | 2.8yrs |
| Durata media del Consiglio di amministrazione | 9.9yrs |
Aggiornamenti recenti sulla gestione
Recent updates
Cassava Sciences: Turning The Corner Into A Brick Wall
Jul 24Cassava Sciences (NASDAQ:SAVA) Is In A Good Position To Deliver On Growth Plans
Oct 17
We're Hopeful That Cassava Sciences (NASDAQ:SAVA) Will Use Its Cash Wisely
Jul 04We're Not Very Worried About Cassava Sciences' (NASDAQ:SAVA) Cash Burn Rate
Mar 05Cassava Sciences (NASDAQ:SAVA) Is In A Good Position To Deliver On Growth Plans
Nov 19Cassava Sciences begins extension study of Alzheimer's drug simufilam
Oct 13Cassava Sciences Stock: Huge Returns Or Catastrophic Losses
Sep 29Cassava Sciences: Trying To Manage Expectations
Sep 21Cassava Sciences reaches over five-month high on rising volumes
Sep 09Cassava Sciences Looks As Good Of A Purchase As Ever
Sep 03Cassava Sciences stock jumps 10% after director buys $860K shares
Aug 26Cassava Sciences rally continues as stock up 39%
Aug 17Cassava's Simufilam And Acetylcholinesterase Inhibitors: Similar Results
Aug 11Cassava Sciences GAAP EPS of -$0.48 misses by $0.06
Aug 03We're Hopeful That Cassava Sciences (NASDAQ:SAVA) Will Use Its Cash Wisely
Aug 03Cassava Sciences sheds 44% on report of criminal probe linked to Alzheimer’s drug
Jul 27Cassava Sciences And Alzheimer's Disease: A Precipitious Path
Jun 10Cassava Sciences: 3 Upcoming Catalysts That Could Decide Bull / Bear Debate
May 31Cassava Sciences (NASDAQ:SAVA) has More Than Enough Funding to Function Until the Approval Process is Finished, but Investors may Need to be Ready for a Long Wait
Apr 193 Key Points To Remember About Cassava Sciences
Apr 07Retractions Of A Key Collaborator's Papers Set Up A Big April For Cassava Sciences
Mar 31Cassava Sciences: Why The Stock Is Rangebound
Feb 28The FDA Deals Another Blow To Cassava Sciences' Bears
Feb 11Cassava Sciences, Inc.: Recent Trading Activity Presents An Opportunity
Feb 02INmune Bio, The Biotech In My Stable For After Cassava Sciences
Jan 17Cassava Sciences, Inc. - The Short Squeeze Has Started
Jan 06Cassava Sciences, Inc. - A Rational Expectation If All Goes Well With Simufilam
Dec 30Companies Like Cassava Sciences (NASDAQ:SAVA) Are In A Position To Invest In Growth
Dec 28Cassava Sciences Stock: Here We Go Again
Dec 21Cassava Sciences Teaches Us 4 Lessons To Find The Next Big Thing
Dec 02Cassava Sciences Gets Underway Putting Simufilam To The Test
Nov 24Cassava Sciences: Data Rules!
Nov 17Cassava Sciences' Hypothesis Raises Doubts
Nov 08AMMINISTRATORE DELEGATO
Rick Barry (65 yo)
no data
Mandato
US$546,155
Compensazione
Mr. Richard Jon Barry, also known as Rick, served as Independent Director at Cassava Sciences, Inc. since June 11, 2021, until July 17, 2024 and serves as its Executive Chairman of the Board since July 17,...
Gruppo dirigente
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| CEO & Director | no data | US$546.16k | 0.98% $ 15.0m | |
| Chief Financial Officer | 5.9yrs | US$2.99m | 0.049% $ 742.6k | |
| Senior VP | 1.9yrs | US$1.27m | 0% $ 0 | |
| Chief Medical Officer | 3.7yrs | US$2.97m | 0.0083% $ 127.5k | |
| Senior Vice President of Technology | no data | Nessun dato | Nessun dato | |
| Senior Vice President of Technical Operations | no data | Nessun dato | Nessun dato | |
| Senior Vice President of Regulatory Affairs | 1.8yrs | Nessun dato | Nessun dato | |
| Senior Vice President of Neuroscience | 4.4yrs | Nessun dato | Nessun dato |
2.8yrs
Durata media
62.5yo
Età media
Gestione esperta: Il team dirigenziale di SAVA è considerato esperto (durata media dell'incarico 2.8 anni).
Membri del Consiglio di amministrazione
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| CEO & Director | 3.3yrs | US$546.16k | 0.98% $ 15.0m | |
| Lead Independent Director | 26yrs | US$546.16k | 2.37% $ 36.2m | |
| Independent Director | 16.8yrs | US$438.42k | 0.0025% $ 38.2k | |
| Independent Director | 26.3yrs | US$438.42k | 0.017% $ 262.8k | |
| Member of Scientific Advisory Board | 9.9yrs | US$558.31k | Nessun dato | |
| Independent Director | 21.5yrs | US$546.16k | 0.027% $ 405.9k | |
| Independent Chairman | less than a year | US$474.50k | 0% $ 0 | |
| Independent Director | less than a year | US$474.50k | 0% $ 0 | |
| Independent Director | less than a year | US$474.50k | 0% $ 0 |
9.9yrs
Durata media
71yo
Età media
Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di SAVA sono considerati esperti (durata media dell'incarico 9.8 anni).